CAMBRIDGE, Mass.--(BUSINESS WIRE)--Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019. Now, Elicio ...
Research conducted at the Irvine Lab at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology is being utilized in Elicio's AMP-CAR-T Platform Activation of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, ...
Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a fast and cost-effective method to test liquids for a ubiquitous family of chemical ...
Elicio Therapeutics, a clinical-stage biotechnology company (Nasdaq: ELTX) has recently announced the results from the Phase 1 AMPLIFY-201 study on ELI-002. This immunotherapy uniquely targets ...
Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a fast and cost-effective method to test liquids for a ubiquitous family of chemical ...
Efficacy and safety of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer: A prospective multicenter phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results